Lidocaine‐induced potentiation of thermal damage in skin and carcinoma cells

• DOI: 10.1002/lsm.23027
• Publication Date: 2018-10-15T13:40:53Z
• Authors: Adam B. Raff; Carina N. Thomas; Gary S. Chuang; Mathew M. Avram; Monica H. Le; R. Rox Anderson; Martin Purschke
• Keywords: 0301 basic medicine; 0303 health sciences; Skin Neoplasms; Cell Survival; Cell Cycle; Lidocaine; Hyperthermia, Induced; 01 natural sciences; 3. Good health; Cell Line; 03 medical and health sciences; 0302 clinical medicine; Cell Line, Tumor; 0103 physical sciences; Humans; Skin

Objective Lidocaine acts as a local anesthetic by blocking transmembrane sodium channel permeability, but also induces the synthesis of heat shock proteins and sensitizes cells to hyperthermia. A previous study reported two cases deep focal skin ulceration at points corresponding depot lidocaine injection sites after treatment with non‐ablative fractional resurfacing it was hypothesized that had focally sensitized keratinocytes thermal damage laser treatment. The objective this investigate whether potentiates hyperthermia both normal cancerous using an in vitro model. Methods Normal cell lines (fibroblasts, keratinocytes), cancer (melanoma, basal carcinoma), mucosal line (cervical carcinoma) were exposed various concentrations (0–0.3%) or without (37°C, 42°C). Results Compared cells, we demonstrate show significantly increased toxicity when moderate temperature (42°C) low (0.1–0.2%) are combined. directly correlates higher percentage S‐phase (28–57%) compared (13–19%; R‐square 0.6752). Conclusion These results suggest sensitivity cycle active cells. direct correlation between could be harnessed selectively treat while sparing surrounding tissue. Additional research pre‐clinically clinically several different sources (e.g., lasers, ultrasound, etc.) is needed confirm optimize these results. Lidocaine‐enhanced may provide non‐invasive, alterative option for highly proliferating, superficial skin, lesions such warts. Lasers Surg. Med. 51:88–94, 2019. © 2018 Wiley Periodicals, Inc.